Clinical trials: Philadelphia-Negative ALL
Leukemia
Interferon Alfa Plus Sargramostim in Treating Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia
RATIONALE: Interferon alfa may interfere with the growth of cancer cells. Colony-stimulating factors such as sargramostim may increase the number of immune cells found in bone marrow or peripheral blood and may help a person's…
- Trial name
- NCT00003561
- Testing
- recombinant interferon alfa, sargramostim
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative, T Acute Lymphoblastic Leukemia
Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia
This phase II trial tests how well etoposide, prednisone, vincristine, cyclophosphamide and doxorubicin (DA-EPOCH) with or without rituximab plus recombinant Erwinia asparaginase (JZP458) works in treating patients with newly…
- Trial name
- NCT06738368
- Testing
- Asparaginase Erwinia chrysanthemi, Biospecimen Collection, Bone Marrow Collection
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Washington
Accelerated Phase Chronic Myelogenous Leukemia, Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative
3-AP and Fludarabine in Treating Patients With Myeloproliferative Disorders, Chronic Myelomonocytic Leukemia, or Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia
This phase II trial is studying how well giving 3-AP together with fludarabine works in treating patients with myeloproliferative disorders (MPD), chronic myelomonocytic leukemia (CMML), or accelerated phase or blastic phase…
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative, Blastic Phase Chronic Myelogenous Leukemia, Chronic Eosinophilic Leukemia
- Trial name
- NCT00381550
- Testing
- fludarabine phosphate, triapine, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- National Cancer Institute (NCI)
Leukemia
STI571 in Treating Patients With Chronic Myelogenous Leukemia in Blast Crisis
RATIONALE: STI571 may interfere with the growth of cancer cells and may be an effective treatment for leukemia. PURPOSE: Phase II trial to study the effectiveness of STI571 in treating patients who have chronic myelogenous…
- Trial name
- NCT00006475
- Testing
- imatinib mesylate
- Where
- United States
- Sponsor
- Novartis
B-Cell Acute Lymphoblastic Leukemia, Adult
Blinatumomab Combined With Venetoclax as Maintenance Therapy After Allo-HSCT in High-risk Ph Negative Acute B-cell Lymphoblastic Leukemia
This study is a single-center, single-arm, prospective clinical trial evaluating the efficacy and safety of blinatumomab combined with venetoclax as maintenance therapy for high-risk Philadelphia chromosome-negative acute B-cell…
- Trial name
- NCT07199855
- Testing
- blinatumomab combined with venetoclax as maintenance therapy
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Zhejiang University
Philadelphia Chromosome Negative Adult B-cell Acute Lymphoblastic Leukemia
Multicenter Trial Treatment of Philadelphia Chromosome Negative B-cell Acute Lymphoblastic Leukemia of Young Adults
The purpose of this study is to prospectively validate the new risk model, based on minimal residual disease (MRD) response level and oncogenetic status by comparing historical results of GRAALL-2005 with those of GRAALL-2014 in…
- Trial name
- GRAALL-2014/B (NCT02617004)
- Where
- France
- Volunteers
- 500 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
B-precursor Acute Lymphoblastic Leukemia
Study to Investigate Intravenous Blinatumomab in Japanese Adult Participants With Newly Diagnosed Philadelphia-negative B-precursor Acute Lymphoblastic Leukemia (B-ALL)
The main objective of the study is to evaluate safety and tolerability of blinatumomab in adult Japanese participants with newly diagnosed B-ALL.
- Trial name
- NCT06649006
- Testing
- Blinatumomab
- Where
- 6 sites in Japan
- Volunteers
- 6 people
- Sponsor
- Amgen
Acute Lymphoblastic Leukemia
SPARK-ALL: Calaspargase Pegol in Adults With ALL
The purpose of this phase 2/3 study is to confirm the recommended doses and to evaluate the safety and pharmacodynamics of Calaspargase pegol for the treatment of adult patients with Philadelphia-negative Acute Lymphoblastic…
- Trial name
- NCT04817761
- Testing
- Calaspargase pegol (S95015)
- Where
- 21 sites in United States
- Volunteers
- 42 people
- Sponsor
- Institut de Recherches Internationales Servier
ALL, Adult, Philadelphia-Negative ALL
RDC-Blinatumomab Versus hyperCVAD for Ph-negative B-ALL.
In this study, newly diagnosed non-elderly patients with Philadelphia chromosomal negative (PH-) B-ALL were enrolled and 1:1 randomised into Reduced-intensity chemotherapy followed by Blinatumomab cohort or hyperCVAD cohort as…
- Trial name
- BEAT-ALL-2024 (NCT06250959)
- Testing
- Blinatumomab Injection [Blincyto], Doxorubicin
- Where
- China
- Volunteers
- 124 people
- Sponsor
- Chen Suning
Untreated Philadelphia Positive Acute Lymphoblastic Leukemia, De Novo
MRD/Risk-oriented Therapy of Adult Ph- ALL Including Pegylated Asparaginase and Lineage-targeted Methotrexate
This study will be conducted in different centres and will study adult patients with Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL).
- Conditions
- Untreated Philadelphia Positive Acute Lymphoblastic Leukemia, De Novo, Secondary, Low-dose Corticosteroids Pretreatment
- Trial name
- LAL1913 (NCT02067143)
- Testing
- Prephase PDN + CY, Cycle 1 Induction, Cycle 2 Induction / Early consolidation
- Where
- 61 sites in Italy
- Volunteers
- 204 people
- Sponsor
- Gruppo Italiano Malattie EMatologiche dell'Adulto
Myeloproliferative Neoplasms (MPN), Polycythemia Vera (PV)
Screening for Asymptomatic Portal Vein Thrombosis and Portal Hypertension in Patients With Philadelphia Negative Myeloproliferative Neoplasms
This study involves screening for portal vein thrombosis and portal hypertension in patients with Philadelphia negative myeloproliferative neoplasms (MPNs).
- Conditions
- Myeloproliferative Neoplasms (MPN), Polycythemia Vera (PV), Essential Thrombocythemia (ET), Myelofibrosis (MF)
- Trial name
- NCT01816256
- Testing
- Upper gastrointestinal endoscopy and Doppler ultrasound
- Where
- 2 sites in Canada
- Volunteers
- 102 people
- Sponsor
- University Health Network, Toronto
Leukemia, Lymphoma
Combination Chemotherapy Followed by Donor Bone Marrow Transplant or Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer or Genetic Disorders
RATIONALE: Giving chemotherapy drugs, such as fludarabine and melphalan, before a donor bone marrow transplant or peripheral blood stem cell transplant helps stop the patient's immune system from rejecting the donor's stem cells…
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Trial name
- NCT00008307
- Testing
- anti-thymocyte globulin, cyclosporine, fludarabine phosphate
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- Herbert Irving Comprehensive Cancer Center
Leukemia
Interferon Alfa in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia
RATIONALE: Interferon alfa may interfere with the growth of cancer cells. Low doses of interferon alfa may be as effective as high doses.
- Trial name
- NCT00002869
- Testing
- recombinant interferon alfa, cytarabine, hydroxyurea
- Where
- United Kingdom
- Volunteers
- 800 people
- Sponsor
- Medical Research Council
Philadelphia Negative Myeloproliferative Neoplasms
Cardiovascular Manifestations in Ph-negative MPN
The primary aim of this research is to investigate the clinical and subclinical cardiovascular complications and its relationship with myeloproliferative neoplasms seeking to assess incidence, prevalence and severity in…
- Trial name
- NCT06615414
- Testing
- participants are not assigned an intervention as part of the study
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Assiut University
Myelofibrosis (MF), Polycythemia Vera
MPNdpoint. Single-center, Retrospective, Prospective Study of the Outcome of Patients With Philadelphia-negative Chronic Myeloproliferative Neoplasms
Chronic myeloproliferative neoplasms (MPNs) are hematologic disorders of the myeloid lineage characterized by clonal proliferation of hematopoietic stem cells, high risk of thrombotic-hemorrhagic complications, and transformation…
- Conditions
- Myelofibrosis (MF), Polycythemia Vera, Essential Thrombocythaemia
- Trial name
- NCT07863466
- Where
- Italy
- Volunteers
- 1,190 people
- Sponsor
- Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative
Full-course Immunotherapy Combined With Chemotherapy in Newly Diagnosed B-cell Acute Lymphoblastic Leukemia
This is a single-arm, prospective, phase 2 clinical trial evaluating the improvement of survival outcomes of blinatumomab combined with chemotherapy as a full-course treatment regimen in patients with newly diagnosed Philadelphia…
- Trial name
- FLOW (NCT07564453)
- Testing
- Blinatumomab, Induction Chemotherapy, Hyper-CVAD
- Where
- China
- Volunteers
- 101 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Philadelphia Chromosome Negative ALL, Acute Lymphoblastic Leukemia, Adult
Efficacy and Safety of Chemotherapy Combined With CAR-T Cells in Newly Diagnosed Adult Patients With Ph- B-ALL
In recent years, immunotherapy (eg. blinatumomab, inotuzumab ozogamicin, CAR-T cells) has demonstrated a high safety and efficacy profile in relapsed/refractory (R/R）B-ALL.
- Trial name
- NCT06481241
- Testing
- CAR-T cells, Venetoclax
- Where
- China
- Volunteers
- 77 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Philadelphia Chromosome Negative B-cell Precursor Acute Lymphoblastic Leukemia
A Study Evaluating Subcutaneous Versus Intravenous Blinatumomab in Newly Diagnosed Adults With B-cell Precursor Acute Lymphoblastic Leukaemia
The main objective of this trial is to demonstrate that subcutaneous (SC) blinatumomab in conjunction with chemotherapy (Arm B) is non-inferior to continuous intravenous infusion (cIV) blinatumomab in conjunction with…
- Trial name
- AUDAX (NCT07223190)
- Testing
- Blinatumomab, HyperCVAD
- Volunteers
- 560 people
- Sponsor
- Amgen
Philadelphia Chromosome-negative or BCR-ABL-negative, CD19-positive ALL
PETHEMA-BLIN-01/PET069014 (BLIN-01)
The PETHEMA Spanish group treats patients with high-risk Philadelphia chromosome-negative ALL, aged 18 to 55 years, based on the MRD clearance as assessed by flow cytometry at a centralised evaluation centre.
- Trial name
- NCT03523429
- Testing
- blinatumomab
- Where
- 12 sites in Spain
- Volunteers
- 11 people
- Sponsor
- PETHEMA Foundation
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission
Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies
This phase II trial studies how well cyclophosphamide works in preventing chronic graft-versus-host disease after allogeneic peripheral blood stem cell transplant in patients with hematological malignancies.
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Myeloid Leukemia in Remission
- Trial name
- NCT01427881
- Testing
- cyclophosphamide, cyclosporine, peripheral blood stem cell transplantation
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- Fred Hutchinson Cancer Center